Form 4 for BVS Bioventus Inc.
Accepted 2022-02-14 00:00:00 ET · period of report 2022-02-10 · accession 0000899243-22-006332 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-14 | 2022-02-10 | BVS | Nosenzo John | Chief COMMERCIAL Off | M - OptEx | — | +66.1K | 66.6K | +13,228% | — |
| D | 2022-02-14 | 2022-02-10 | BVS | Nosenzo John | Chief COMMERCIAL Off | F - Tax | $12.88 | +24.2K | 42.4K | +133% | +$311.8K |
| D | 2022-02-14 | 2022-02-10 | BVS | Nosenzo John | Chief COMMERCIAL Off | M - OptEx | $0.00 | -66.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-02-10 | M | A | 66,139 | — | 66,639 | D | — | — | (F1) Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. |
| 2 | Common | Class A Common Stock | 2022-02-10 | F | A | 24,205 | $12.88 | 42,434 | D | — | — | |
| 3 | Derivative | Phantom Profit Units | 2022-02-10 | M | D | 66,139 | $0.00 | 0 | D | — · — to — | 66,139 Class A Common Stock | (F1) Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. |